EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte‐rich tumours

Irena Antonia Ungureanu iD, Fleur Cohen-Aubart, Sébastien Héritier, Julien Haroche, Jean Donadieu, Jean-François Emile

Histopathology · 2023-08 · 83 (2) · 320-325

DOI: 10.1111/his.14909 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, online erschienen am 03.04.2023. Verfasst von Irena Antonia Ungureanu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, Paris-Saclay University, Versailles SQY University (UVSQ), EA4340-BECCOH, Assistance Publique-Hôpitaux de Paris (APHP), Ambrois…. Hauptthemen laut MEDLINE: Histiocytosis, Histiocytosis, Langerhans-Cell, Histiocytosis, Sinus, Erdheim-Chester Disease. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Association Pour la Recherche et L'enseignement en Pathologie, French National Cancer Institute, Institut National Du Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The aim was to test the expression of PU.1 on different types of histiocytoses and to test the utility of PU.1 in confirming or excluding a histiocytic origin in tumour samples with suspicion of histiocytosis. Methods and Results We analysed 66 biopsies of nonmalignant histiocytoses represented by Langerhans‐cell histiocytosis ( n = 13), Erdheim–Chester disease (ECD) ( n = 19), Rosai–Dorfman disease (RDD) ( n = 14), mixed ECD‐RDD ( n = 3), ALK‐positive histiocytosis ( n = 6), and juvenile xanthogranuloma ( n = 11). All cases were positive for PU.1 in reactive and neoplastic histiocytes. In addition, 39 cases of tumours with high‐grade cytological atypia were referred to our center as suspicion of malignant histiocytosis/histiocytic sarcoma and only 18 were confirmed. Indeed, more than half of these tumours (21/39) were either undifferentiated malignant tumours with a stroma rich in histiocytes, diffuse large B‐cell lymphoma, or high‐grade dedifferentiated liposarcoma. PU.1 was useful to distinguish between the negativity of large atypical nuclei and the positivity of stromal reactive histiocytes.

Conclusion

PU.1 is expressed by all types of histiocytosis. It distinguishes histiocytosis from histiocyte‐rich tumours with an easy interpretation due to its sharp nuclear staining. Its negativity in lesional/tumour cells in histiocyte‐like lesions is useful to eliminate a histiocytosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HistiocytosisHistiocytosis, Langerhans-CellHistiocytosis, SinusErdheim-Chester DiseaseHematologic NeoplasmsHumansHistiocytes

Stichwörter der Autor:innen

histiocyte-richhistiocytosismalignant tumourspu.1

Autor:innen und Institutionen

  • Pathology Department, Paris-Saclay University, Versailles SQY University (UVSQ), EA4340-BECCOH, Assistance Publique-Hôpitaux de Paris (APHP), Ambroise-Paré Hospital, Boulogne, France.
  • Internal Medicine Department 2, French National Referral Center for Rare Systemic Diseases and Histiocytoses, Sorbonne University, APHP, Pitié-Salpêtrière Hospital, Paris, France.
  • Pediatric Hematology Department, Referral Center for Histiocytoses, Sorbonne University, APHP, Armand-Trousseau Hospital, Paris, France.
  • Pediatric Hematology Department, Referral Center for Histiocytoses, UVSQ, EA4340-BECCOH, APHP, Armand-Trousseau Hospital, Paris, France.

ORCID-Profile: Irena Antonia Ungureanu

Förderung

  • Association Pour la Recherche et L'enseignement en Pathologie
  • French National Cancer Institute
  • Institut National Du Cancer

Zitieren

APA

Ungureanu, I. A., Cohen-Aubart, F., Héritier, S., Haroche, J., Donadieu, J., & Emile, J. F. (2023). PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte‐rich tumours. Histopathology, 83(2), 320-325. https://doi.org/10.1111/his.14909

Vancouver

Ungureanu IA, Cohen-Aubart F, Héritier S, Haroche J, Donadieu J, Emile JF. PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte‐rich tumours. Histopathology. 2023;83(2):320-325. doi:10.1111/his.14909

BibTeX
@article{Ungureanu2023,
  author = {Ungureanu, Irena Antonia and Cohen-Aubart, Fleur and Héritier, Sébastien and Haroche, Julien and Donadieu, Jean and Emile, Jean-François},
  title = {PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte‐rich tumours},
  journal = {Histopathology},
  year = {2023},
  volume = {83},
  number = {2},
  pages = {320--325},
  doi = {10.1111/his.14909}
}
Kostenlos starten →